A Phase 3 Trial of l-Glutamine in Sickle Cell Disease

The New England Journal of Medicine
Y NiiharaInvestigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease

Abstract

Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which probably reduces oxidative stress and could result in fewer episodes of sickle cell-related pain. In a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial, we tested the efficacy of pharmaceutical-grade l-glutamine (0.3 g per kilogram of body weight per dose) administered twice daily by mouth, as compared with placebo, in reducing the incidence of pain crises among patients with sickle cell anemia or sickle β0-thalassemia and a history of two or more pain crises during the previous year. Patients who were receiving hydroxyurea at a dose that had been stable for at least 3 months before screening continued that therapy through the 48-week treatment period. A total of 230 patients (age range, 5 to 58 years; 53.9% female) were randomly assigned, in a 2:1 ratio, to receive l-glutamine (152 patients) or placebo (78 patients). The patients in the l-glutamine group had significantly fewer pain crises than those in the placebo group...Continue Reading

References

May 1, 1980·The New England Journal of Medicine·R P HebbelM H Steinberg
Jan 5, 2008·American Journal of Respiratory and Critical Care Medicine·Armand Mekontso DessapBernard Maitre
May 6, 2011·American Journal of Hematology·Erfan NurUNKNOWN CURAMA Study Group
Dec 2, 2011·IUBMB Life·Erica N Chirico, Vincent Pialoux
Dec 14, 2011·Contemporary Clinical Trials·Marlene H Peters-LawrenceUNKNOWN Sickle Cell Disease Clinical Research Network (SCDCRN)
Dec 17, 2011·Journal of Nutrition and Metabolism·Elise Mok, Régis Hankard
Sep 20, 2012·JPEN. Journal of Parenteral and Enteral Nutrition·Milan Holecek
Apr 9, 2013·European Journal of Haematology·Rabindra PaulVictor R Gordeuk
Sep 7, 2016·Southern Medical Journal·John J Strouse
Dec 14, 2016·The New England Journal of Medicine·Kenneth I AtagaRussell P Rother

❮ Previous
Next ❯

Citations

Nov 8, 2018·The New England Journal of Medicine
Dec 1, 2018·Expert Opinion on Pharmacotherapy·Lidiane Torres, Nicola Conran
Jan 27, 2019·American Journal of Hematology·Joseph F Hoffman
Jan 22, 2019·European Journal of Haematology·Andrea PiccinOwen P Smith
Mar 3, 2019·Pediatric Blood & Cancer·Caroline Hastings
Mar 12, 2019·Expert Review of Hematology·Bruno Deltreggia Benites, Sara Teresinha Olalla-Saad
Mar 21, 2019·Current Opinion in Hematology·Anupam AichKalpna Gupta
Jun 15, 2019·The New England Journal of Medicine·Elliott VichinskyUNKNOWN HOPE Trial Investigators
Aug 1, 2019·Expert Review of Hematology·Carlton Dampier
Oct 28, 2019·Blood Advances·Md Nasimuzzaman, Punam Malik
Sep 12, 2019·Blood Advances·Atinuke M Dosunmu-OgunbiAdam C Straub
Oct 30, 2019·Therapeutic Innovation & Regulatory Science·Jitendra Ganju
Jan 18, 2020·Experimental Biology and Medicine·Madeleine LuVivien A Sheehan
Jan 12, 2020·American Journal of Hematology·Martin H Steinberg
Jan 28, 2020·Experimental Biology and Medicine·Alina Sadaf, Charles T Quinn
Oct 1, 2019·Current Opinion in Hematology·Matthew S Karafin, Joshua J Field
Nov 26, 2019·Journal of Pediatric Hematology/oncology·Jefferson N BrownellVirginia A Stallings
Mar 7, 2020·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Susan E CrearyJennifer N Cooper
Mar 7, 2020·British Journal of Haematology·Amina Nardo-MarinoDavid Rees
Apr 6, 2019·Nature Medicine·Chunliang Xu, Paul S Frenette
Apr 7, 2020·The Cochrane Database of Systematic Reviews·Francis I ChinegwundohKofi A Anie
Apr 16, 2020·Journal of Clinical Medicine·Klétigui Casimir DembéléJuan Manuel Chao de la Barca
May 15, 2020·Blood·Victor R Gordeuk
Nov 27, 2019·Database : the Journal of Biological Databases and Curation·UNKNOWN Sickle Cell Disease Ontology Working Group
Apr 18, 2020·European Journal of Haematology·Deepika S DarbariSamir K Ballas
Jul 1, 2020·Pediatric Blood & Cancer·Charleen D Adams
Sep 3, 2020·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Faisal Alsayegh, Shaker A Mousa
Sep 18, 2020·JAAPA : Official Journal of the American Academy of Physician Assistants·Robert J Hehre
Sep 18, 2020·Blood·Daniel B Kim-Shapiro, Mark T Gladwin
Jul 23, 2020·American Journal of Hematology·Victor R GordeukJosef T Prchal
Sep 29, 2020·HemaSphere·Joachim B Kunz, Andreas E Kulozik
Jan 30, 2019·Experimental Biology and Medicine·Nicola Conran, Lidiane Torres
Jan 14, 2020·Pediatric Annals·Sabrina Kimrey, Kay L Saving
Mar 12, 2020·Annals of Hematology·Firdosh Shah, Mitesh Dwivedi
Mar 11, 2020·Frontiers in Pediatrics·Dominik OchocinskiNiranjan Kissoon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

The New England Journal of Medicine
Kenneth I AtagaRussell P Rother
JAMA : the Journal of the American Medical Association
Nicolas StettlerNancy B Walczak
The New England Journal of Medicine
Orrin DevinskyGWPCARE3 Study Group
The New England Journal of Medicine
Matthew M HeeneyDOVE Investigators
© 2022 Meta ULC. All rights reserved